Display options
Cite
Köhli-Wiesner A, Stahlberger L, Bieli C, et al. Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance. J Allergy (Cairo). 2011;2012:790910doi: 10.1155/2012/790910.
Köhli-Wiesner, A., Stahlberger, L., Bieli, C., Stricker, T., & Lauener, R. (2012). Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance. Journal of allergy, 2012790910. https://doi.org/10.1155/2012/790910
Köhli-Wiesner, Alice, et al. "Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance." Journal of allergy vol. 2012 (2012): 790910. doi: https://doi.org/10.1155/2012/790910
Köhli-Wiesner A, Stahlberger L, Bieli C, Stricker T, Lauener R. Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance. J Allergy (Cairo). 2012;2012:790910. doi: 10.1155/2012/790910. Epub 2011 Jul 19. PMID: 21804830; PMCID: PMC3140184.
Copy Download .nbib Format: NLM
Share it on

J Allergy (Cairo). 2012;2012:790910. doi: 10.1155/2012/790910. Epub 2011 Jul 19.

Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance.

Journal of allergy

Alice Köhli-Wiesner, Lisbeth Stahlberger, Christian Bieli, Tamar Stricker, Roger Lauener

Affiliations

  1. Christine Kühne-Center for Allergy Research and Education, University Children's Hospital Zurich, Steinwiesstraße 75, 8032 Zurich, Switzerland.

PMID: 21804830 PMCID: PMC3140184 DOI: 10.1155/2012/790910

Abstract

Background & Objective. Ultrarush induction for specific venom immunotherapy has been shown to be reliable and efficacious in adults. In this study its safety and tolerance in children was evaluated. Methods. Retrospective analysis of 102 ultrarush desensitizations carried out between 1997 and 2005 in 94 children, aged 4 to 15 years. Diagnosis and selection for immunotherapy were according to recommendations of the European Academy of Allergy and Clinical Immunology. Systemic adverse reactions (SARs) were described using the classification of H. L. Mueller. Results. All patients reached the cumulative dose of 111.1 μg hymenoptera venom within 210 minutes. Six patients (6%) had allergic reactions grade I; 2 patients (2%) grade II and 5 patients (5%) grade III. Three patients (3%) showed unclassified reactions. SARs did not occur in the 15 patients aged 4 to 8 years and they were significantly more frequent in girls (29%) compared with boys (12%) (P = 0.034, multivariant analysis) and in bee venom extract treated patients (20%) compared to those treated with wasp venom extract (8%) (OR 0.33, 95% Cl 0.07-1.25). Conclusion. Initiation of specific immunotherapy by ultrarush regimen is safe and well tolerated in children and should be considered for treating children with allergy to hymenoptera venom.

References

  1. Ann Allergy Asthma Immunol. 2004 Apr;92(4):409-13 - PubMed
  2. Clin Ther. 2000 Mar;22(3):351-8 - PubMed
  3. Allergy. 2000 May;55(5):484-8 - PubMed
  4. Allergy. 2005 Dec;60(12):1459-70 - PubMed
  5. J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1231-5 - PubMed
  6. Clin Exp Allergy. 1993 Mar;23(3):226-30 - PubMed
  7. Clin Exp Allergy. 2003 Jan;33(1):58-64 - PubMed
  8. Allergy. 2003 Nov;58(11):1176-9 - PubMed
  9. Clin Exp Allergy. 2008 Mar;38(3):512-9 - PubMed
  10. J Allergy Clin Immunol. 2010 Mar;125(3):569-74, 574.e1-574.e7 - PubMed
  11. Allergy. 2000 Nov;55(11):1005-10 - PubMed
  12. Br Med J (Clin Res Ed). 1983 Nov 5;287(6402):1329-31 - PubMed
  13. J Allergy Clin Immunol. 2001 Jan;107(1):81-6 - PubMed
  14. J Asthma Res. 1966 Jun;3(4):331-3 - PubMed
  15. J Investig Allergol Clin Immunol. 2006;16(2):79-85 - PubMed
  16. Clin Exp Allergy. 1995 Feb;25(2):159-65 - PubMed
  17. Allergy. 1997 Jan;52(1):94-6 - PubMed
  18. Allergy. 1993;48(14 Suppl):36-46 - PubMed

Publication Types